phase 2 trial is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| 长期储存温度 | 约 -20°C 或更低 | 冻干粉常见保存条件 |
| 复溶溶剂 | 注射用水或指定缓冲液 | 按方案或说明书执行 |
| 容器材质 | 低吸附聚丙烯 | 减少多肽在管壁的吸附损失 |
| 主要降解路径 | 脱酰胺、氧化、聚集 | 由序列与工艺条件共同决定 |
| 追溯材料 | 分析证书与批次记录 | 用于来源与纯度核实 |
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
==== Metabolism ==== Minoxidil is a prodrug of minoxidil sulfate, which can be formed both systemically and locally within hair follicles. This active metabolite is 14-fold more potent than minoxidil in stimulating cysteine incorporation in cultured rodent hair follicles ex vivo. Similarly to minoxidil, it also stimulates hair follicle growth. Minoxidil is sulfated into minoxidil sulfate by at least four cytosolic sulfotransferase enzymes found in skin, scalp, smooth muscle, liver, and fibroblasts. The primary sulfotransferase involved in sulfation of minoxidil in hair follicles is SULT1A1, whereas in the liver, it is SULT2A1. Expression of this enzyme has been found to predict the effectiveness of topical minoxidil. Oral minoxidil is subject to first-pass metabolism, including rapid and extensive metabolism in the liver. A majority of orally administered minoxidil, about 90%, is metabolized in the liver via glucuronidation, hydroxylation, and sulfation, with glucuronidation being the primary metabolic pathway and minoxidil glucuronide being the predominant metabolite of minoxidil. Conversely, topical minoxidil bypasses the first pass through the liver and is not subject to first-pass metabolism. Similarly, sublingual minoxidil also bypasses first-pass metabolism.
== Other salvage pathways == L-methionine salvage is the pathway that regenerates methionine from its downstream products. A version of the pathway uses methylthioadenosine (MTA), forming the so-called MTA cycle with its synthesizing reaction. This sulphur-recycling action is found in humans, and seems to be universal among aerobic life. Nicotinate salvage is the process of regenerating nicotinamide adenine dinucleotide from nicotinic acid. This pathway is important for controlling the level of oxidative stress in cells. The human gene NAPRT encodes the main enzyme in the pathway. Cancer cells, which have increased NAD requirements, tend to upregulate the pathway. Salvage pathways also exist for ceramide, cobalamin, cell wall components, and tetrahydrobiopterin in various organisms.
Prokaryotes are not as structurally complex as eukaryotes, and were once thought to have little internal organization, and lack cellular compartments and internal membranes; but slowly, details are emerging about prokaryotic internal structures that overturn these assumptions. An early false turn was the idea developed in the 1970s that bacteria might contain cell membrane folds termed mesosomes, but these were later shown to be artifacts produced by the chemicals used to prepare the cells for electron microscopy. However, there is increasing evidence of compartmentalization in at least some prokaryotes. Research has revealed that at least some bacteria have microcompartments, such as carboxysomes. These subcellular compartments are 100–200 nm in diameter and are enclosed by a shell of proteins. Even more striking is the description of membrane-bound magnetosomes in magnetotactic bacteria, reported in 2006. The bacterial phylum Planctomycetota has revealed a number of compartmentalization features. The Planctomycetota cell plan includes intracytoplasmic membranes that separates the cytoplasm into paryphoplasm (an outer ribosome-free space) and pirellulosome (or riboplasm, an inner ribosome-containing space). Membrane-bounded anammoxosomes have been discovered in five Planctomycetota "anammox" genera, which perform anaerobic ammonium oxidation. In the Planctomycetota species Gemmata obscuriglobus, a nucleus-like structure surrounded by lipid membranes has been reported. Compartmentalization is a feature of prokaryotic photosynthetic structures.
== Overdose == Psilocybin has low toxicity, meaning that it has a low risk of inducing life-threatening events like breathing or heart problems. Research shows that health risks may develop with use of psilocybin. Nonetheless, hospitalizations from it are rare, and overdoses are generally mild and self-limiting. The lethal dose of psilocybin in humans is unknown, but has been estimated to be approximately 200 times a typical recreational dose. A review of the management of psychedelic overdoses suggested that psilocybin-related overdose management should prioritize managing the immediate adverse effects, such as anxiety and paranoia, rather than specific pharmacological interventions, as psilocybin's physiological toxicity tends to be rather limited. One analysis of people hospitalized for psilocybin poisoning found high urine concentrations of phenethylamine (PEA), suggesting that PEA might contribute to the effects of psilocybin poisoning. Despite acting as non-selective serotonin receptor agonists, psilocybin and other major serotonergic psychedelics like lysergic acid diethylamide (LSD) do not cause serotonin syndrome even in the context of extreme overdose. This is thought to be because they act as partial agonists of serotonin receptors like the serotonin 5-HT2A receptor, in contrast to serotonin itself, which is a full agonist. In rats, the median lethal dose (LD50) of psilocybin when administered orally is 280 mg/kg, approximately 1.5 times that of caffeine.
Sources: en.wikipedia.org
==== Primary ==== Bush portrayed himself as a compassionate conservative, implying he was more centrist than other Republicans. He campaigned on a platform which included bringing integrity and honor back to the White House, increasing the size of the military, cutting taxes, improving education, and aiding minorities. By early 2000, the race had centered on Bush and Arizona senator John McCain. Bush won the Iowa caucuses and, although heavily favored to win the New Hampshire primary, trailed McCain by 19% and lost. Despite this, he regained momentum and effectively became the front runner after the South Carolina primary, which according to The Boston Globe made history for his campaign's negativity. The New York Times described it as a smear campaign.
A comprehensive article on fluorescent proteins at Scholarpedia Brief summary of landmark GFP papers Interactive Java applet demonstrating the chemistry behind the formation of the GFP chromophore Video of 2008 Nobel Prize lecture of Roger Tsien on fluorescent proteins Excitation and emission spectra for various fluorescent proteins Green Fluorescent Protein Chem Soc Rev themed issue dedicated to the 2008 Nobel Prize winners in Chemistry, Professors Osamu Shimomura, Martin Chalfie and Roger Y. Tsien Molecule of the Month, June 2003: an illustrated overview of GFP by David Goodsell. Molecule of the Month, June 2014: an illustrated overview of GFP-like variants by David Goodsell. Green Fluorescent Protein on FPbase, a fluorescent protein database Overview of all the structural information available in the PDB for UniProt: P42212 (Green fluorescent protein) at the PDBe-KB.
studies showed that betatrophin could increase the quantity of cells that produce insulin in mice quickly. Others showed that the circulating level of betatrophin in T2DM patient blood was higher than that in control groups. Expression of betatrophin correlates with β cell proliferation. Transient expression of betatrophin in mouse liver significantly and specifically promotes pancreatic β cell proliferation, expands β cell mass, and improves glucose tolerance. Thus, betatrophin treatment could augment or replace insulin injections by increasing the number of endogenous insulin-producing cells in diabetics.
With Shahbaz Rana writing that the "PM had "clipped" the Finance Minister’s "decision-making wings" by depriving him of the ECC. The decision to place Aurangzeb as chairman also came after criticism from "all quarters." Pakistan newspaper Dawn, quoting a senior member of the cabinet officially stated that the PM had “regretted he would be unable to chair the ECC meetings due to his hectic schedule and engagements.” On 28 March the Cabinet Committee on Inter-Governmental Commercial Transactions (CCoIGCT) would be constituted, chaired by Khawaja Asif, with Terms of Reference (ToR) that the committee may authorize, recommend approval, and constitute a negotiation committee for a G2G or commercial agreement with a foreign state, as well as approve price-discovery mechanisms, submit recommendations for existing regulatory compliance. Operating under the clauses (c) and (d) of sub-section (2) of Section (4) of the Inter-Governmental Commercial Transactions Act, 2022.
Diisopropyl fluorophosphate (DIFP) is an irreversible inhibitor that blocks the action of serine protease. When it binds to the enzyme a nucleophilic substitution reaction occurs and releases one hydrogen fluoride molecule. The OH group in the active site acts as a nucleophile to attack the phosphorus in DIFP and form a tetrahedral intermediate and release a proton. Then the P-F bond is broken, one electron is transferred to the F atom and it leaves the intermediate as F− anion. It combines with a proton in solution to form one HF molecule. A covalent bond formed between the active site and DIFP, so the serine side chain is no longer available to the substrate.
Sources: en.wikipedia.org
常用质谱测定分子量，再结合肽图或序列分析验证一级结构。单一检测手段一般难以排除结构相近的类似物。多种方法相互印证更为可靠。
低温可以降低水解与聚集的速率，从而延缓降解进程。温度反复波动本身也可能造成相变与样品损失。稳定的储存条件是可重复结果的前提。
分析证书、批次编号、所用检测方法与结果，以及标称储存条件。缺少方法细节的报告难以独立复核。记录完整性决定了追溯能否成立。
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.